Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer
作者： Niels Reinmuth , Burkhard Brandt , Michael Semik , Wolf-Peter Kunze , Richard Achatzy
DOI: 10.1016/S0169-5002(02)00009-0
关键词:
摘要: Abstract Purpose: The aim of this prospective study was to assess the prognostic impact serum tumor markers (Cyfra21-1, carcinoembryonic antigen, neuron-specific enolase, squamous cell carcinoma-antigen and TPAcyk) in patients with non-small lung cancer (NSCLC) receiving complete resection. Methods: Sixty-seven histologically proven NSCLC resection stage I–IIIA disease were included. levels all measured using commercially available immunoassays. Results: With a median follow-up 86 months for surviving patients, those initial Cyfra21-1 higher than 3.57 ng/ml had significantly worse prognosis ( P =0.014). remaining showed no impact. In Cox regression model, proved be an independent factor both overall survival disease-free interval. addition, sustained as completely resected I/II disease. Conclusions: cut-off value ng/ml, Cyfra 21-1 NSCLC-patients Further evaluation is needed, particularly When confirmed larger patient numbers may contribute identification stratification variables future treatment approaches NSCLC.
elsevier.com
sci-hub.se 参考文章(32)
M. Szturmowicz, A. Sakowicz, P. Rudzinski, J. Zych, E. Wiatr, J. Zalęska, E. Rowinska-Zakrzewska, The clinical value of Cyfra 21-1 estimation for lung cancer patients International Journal of Biological Markers. ,vol. 11, pp. 172- 177 ,(1996) , 10.1177/172460089601100306
Hans-Georg Velcovsky, Erich Eigenbrodt, Joachim Schneider, Kathleen Neu, Norbert Katz, Harald Morr, Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Research. ,vol. 20, pp. 5053- 5058 ,(2000)
Wolfgang Fischbach, Berthold Jany, Neuron-specific enolase in the diagnosis and therapy monitoring of lung cancer: a comparison with CEA, TPA, ferritin and calcitonin. International Journal of Biological Markers. ,vol. 1, pp. 129- 136 ,(1986) , 10.1177/172460088600100303
Emilio Bombardieri, Paolo Foa, Luigi Santambrogio, Sarah Caldiera, Monica Fornier, Marco Sala, Ignazio Cataldo, Ettore Seregni, Rosalba Miceli, Mario Nosotti, Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Research. ,vol. 19, pp. 3613- 3618 ,(1999)
DesmondN Carney, DanielC Ihde, MartinH Cohen, PaulJ Marangos, PaulA Bunn, JohnD Minna, AdiF Gazdar, Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. The Lancet. ,vol. 319, pp. 583- 585 ,(1982) , 10.1016/S0140-6736(82)91748-2
Jack A Roth, E.Neely Atkinson, Frank Fossella, Ritsuko Komaki, M.Bernadette Ryan, J.B Putnam, Jin Soo Lee, Hari Dhingra, Louis De Caro, Marvin Chasen, Waun Ki Hong, Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer Lung Cancer. ,vol. 21, pp. 1- 6 ,(1998) , 10.1016/S0169-5002(98)00046-4
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Clifton F. Mountain, Revisions in the International System for Staging Lung Cancer Chest. ,vol. 111, pp. 1710- 1717 ,(1997) , 10.1378/CHEST.111.6.1710
J.M. Bréchot, S. Chevret, J. Nataf, C. Le Gall, J. Frétault, J. Rochemaure, Cl. Chastang, Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. European Journal of Cancer. ,vol. 33, pp. 385- 391 ,(1997) , 10.1016/S0959-8049(97)89010-7
M Díez, A Torres, ML Maestro, MD Ortega, A Gómez, M Pollán, JA Lopez, A Picardo, F Hernando, JL Balibrea, Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. British Journal of Cancer. ,vol. 73, pp. 1248- 1254 ,(1996) , 10.1038/BJC.1996.239